HomeCompareLFLY vs MRK

LFLY vs MRK: Dividend Comparison 2026

LFLY yields 5.41% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $2.2K in total portfolio value· pulled ahead in Year 4
10 years
LFLY
LFLY
● Live price
5.41%
Share price
$37.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.5K
Annual income
$763.44
Full LFLY calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — LFLY vs MRK

📍 MRK pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLFLYMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LFLY + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LFLY pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LFLY
Annual income on $10K today (after 15% tax)
$459.46/yr
After 10yr DRIP, annual income (after tax)
$648.92/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, MRK beats the other by $158.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LFLY + MRK for your $10,000?

LFLY: 50%MRK: 50%
100% MRK50/50100% LFLY
Portfolio after 10yr
$29.6K
Annual income
$856.87/yr
Blended yield
2.89%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

LFLY
Analyst Ratings
3
Buy
1
Hold
Consensus: Buy
Altman Z
-5.8
Piotroski
4/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LFLY buys
0
MRK buys
0
No recent congressional trades found for LFLY or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLFLYMRK
Forward yield5.41%3.25%
Annual dividend / share$2.00$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR0%8.2%
Portfolio after 10y$28.5K$30.7K
Annual income after 10y$763.44$950.29
Total dividends collected$6.6K$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: LFLY vs MRK ($10,000, DRIP)

YearLFLY PortfolioLFLY Income/yrMRK PortfolioMRK Income/yrGap
1$11,241$540.54$11,192$351.54+$49.00LFLY
2$12,595$567.85$12,524$392.70+$71.00LFLY
3$14,072$594.66$14,015$438.65+$57.00LFLY
4← crossover$15,677$620.90$15,682$489.96$5.00MRK
5$17,421$646.50$17,547$547.23$126.00MRK
6$19,312$671.42$19,632$611.16$320.00MRK
7$21,360$695.60$21,963$682.53$603.00MRK
8$23,574$719.01$24,571$762.18$997.00MRK
9$25,966$741.64$27,486$851.08$1.5KMRK
10$28,547$763.44$30,745$950.29$2.2KMRK

LFLY vs MRK: Complete Analysis 2026

LFLYStock

Leafly Holdings, Inc. owns and operates a platform to provide consumers with cannabis information and connects consumers to cannabis brands and licensed retailers. It offers subscription-based marketplace listings, digital advertising solutions, and software as a service-based tools to cannabis retailers and brands; and information, reviews, menus, and ordering and delivery options to its audience through its website and mobile applications. The company was founded in 2010 and is headquartered in Seattle, Washington.

Full LFLY Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this LFLY vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LFLY vs SCHDLFLY vs JEPILFLY vs OLFLY vs KOLFLY vs MAINLFLY vs JNJLFLY vs ABBVLFLY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.